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Abstract
Objectives To study the results of chemotherapy com-
bined with intravesical hyperthermia in patients with
mainly BCG-failing carcinoma in situ (CIS).
Methods Patients with histologically conWrmed CIS were
included retrospectively. Outpatient thermochemotherapy
treatment was done with mitomycin-C (MMC) and the
Synergo® system SB-TS 101 (temperature range between
41 and 44°C), weekly for 6–8 weeks, followed by 4–6 ses-
sions every 6–8 weeks.
Results Fifty-one patients were treated between 1997 and
2005 from 15 European centers. Thirty-four were pre-
treated with BCG. Mean age was 69.9 years. Twenty-four
patients had concomitant papillary tumors. The mean num-
ber of hyperthermia/MMC treatments per patient was 10.0.
Of the 49 evaluable patients 45 had a biopsy and cytology
proven complete response. In two patients CIS disappeared,
but they had persistent papillary tumors. Follow-up of 45
complete responders showed 22 recurrences after a mean of
27 months (median 22): T2 (4), T1 (4), T1/CIS (1), CIS (5),
Ta/CIS (2), Ta (5) and Tx (1). Side eVects (bladder com-
plaints) were generally mild and transient.
Conclusions In patients with primary or BCG-failing CIS,
treatment with intravesical hyperthermia and MMC appears
a safe and eVective treatment. The initial complete response
rate is 92%, which remains approximately 50% after
2 years.
Keywords Bladder cancer · CIS · Hyperthermia · 
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Introduction
Carcinoma in situ (CIS) of the urinary bladder is deWned as
non-papillary high-grade non-invasive urothelial cell carci-
noma (UCC). It is an aggressive form of non-muscle inva-
sive bladder cancer (NMIBC) with a high progression rate
and an even higher recurrence rate [1]. In case of concomi-
tant high-grade pT1 tumors the prognosis is even worse [2].
Even when patients are treated with cystectomy, the pres-
ence of CIS is an adverse prognostic sign [3, 4]. Current
standard therapy in case of CIS is intravesical Bacillus Cal-
mette–Guérin (BCG). Although 30–40% of patients do not
respond to one course of six instillations, half of these still
achieve a complete response after an additional course of
six instillations [5]. Consequently, the treatment guideline
in CIS patients is maintenance BCG [6, 7]. The disadvan-
tage of BCG in comparison with intravesical chemotherapy
is the increased frequency and severity of side eVects.
Alternative therapies for BCG in primary CIS patients
remain experimental or are insuYciently documented.
In case of BCG-refractory CIS, cystectomy is the treat-
ment of choice [8]. Intravesical approaches have failed,
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such as valrubicin [9], are investigational, such as gemcita-
bine [10] and mycobacterial cell wall preparations [11], or
eYcacy should be conWrmed, such as the combination of
BCG and interferon-alpha 2b [12]. Device-assisted strate-
gies for primary CIS include photodynamic therapy (PDT),
electromotive drug administration (EMDA) and the combi-
nation of intravesical hyperthermia and chemotherapy
(thermochemotherapy). PDT has some encouraging results
[13] and sequential BCG with EMDA/mitomycin-C
(MMC) is emerging [14].
Thermochemotherapy (MMC/hyperthermia) has proven
to be more eVective than MMC alone for patients with Ta-1
G1-3 NMIBC in comparative studies with ablative [15] as
well as prophylactic intent [16]. Gofrit et al. [17] reported a
beneWcial prophylactic eVect of thermochemotherapy in
patients with G3 tumors, 15/24 (62.5%) patients were
recurrence-free after a mean follow-up of 35.3 months. In
addition, ablation of high-grade tumors was achieved in 21/
28 (75%) patients, of whom 81% remained tumor free after
a mean follow-up of 20 months. Van der Heijden et al. [18]
reported the use of thermochemotherapy with prophylactic
intent in 90 patients with intermediate and high risk
NMIBC. After 1 and 2 years of follow-up, respectively,
14.3 and 24.6% of all patients experienced a recurrence. In
41 patients previously failing BCG treatment, the recur-
rence rates, respectively, were 23 and 41%.
In the current study, we report for the Wrst time the




Retrospectively, data of all patients treated with MMC in
combination with hyperthermia were gathered from 15 cen-
ters. Of these, patients with biopsy proven and histologi-
cally conWrmed CIS were eligible for analysis. Patients
were included with a WHO performance status of 0–2 and a
life expectancy of more than 24 months. Criteria for ineligi-
bility were a limited bladder capacity (<150 ml), any con-
comitant malignancy, extravesical UCC and the presence of
a diverticulum of the bladder. Patients without follow-up
cystoscopy or with less than six treatments were excluded
from the analysis.
Treatment
The treatment set up has been described in detail before
[19]. In short, the Synergo® system SB-TS 101 is used to
deliver local microwave induced hyperthermia and intra-
vesical chemotherapy simultaneously. This system consists
of a 915 MHz intravesical microwave applicator that deliv-
ers hyperthermia to the bladder wall via direct irradiation.
The hyperthermia range is between 41 and 44°C, controlled
by  Wve thermocouples integrated in a specially designed
20°F treatment catheter. To avoid urethral overheating and
disintegration of MMC, the solution is continuously
pumped out of the bladder and re-instilled after being
cooled. Treatment was done with 20 mg MMC (Kyowa
Hakko Kogyo Co., Tokyo, Japan) in 50 ml sterile water,
replaced by a fresh identical solution after 30 min (a total of
40 mg MMC in 1 h), on an outpatient basis weekly for
6 weeks (prophylactic schedule), followed by six mainte-
nance instillations (one instillation every 6 weeks). Patients
whose concomitant papillary tumors were not or could not
be completely resected, or patients with wide areas of CIS,
were treated with a higher dose of MMC (twice 40 mg, a
total of 80 mg in 1 h), weekly for 8 weeks (ablative sched-
ule), followed by six maintenance instillations of twice
20 mg MMC (one instillation every 6 weeks). In case of
bacterial cystitis or signiWcant hematuria, treatment delay
was recommended.
Follow-up
Cystoscopy and urine cytology were repeated every
3 months for a follow-up period of 24 months. Biopsies
from suspicious lesions were performed. The primary end-
point of the study was eradication of CIS, proven by cystos-
copy, biopsy and cytology. Secondary end-point was either
a pathology proven tumor recurrence, or a clear cystoscopi-
cal recurrence indicated by the investigator. Side eVects and
adverse events were noted in the patient’s Wle. Data were
collected during treatment and follow-up.




In total 51 patients with CIS were included between March
1997 and June 2005 from centers in Israel, Italy, Germany,
Switzerland, Austria and the Netherlands. Mean age was
69.9 years (50–87), with a male-to-female ratio of 4:1 (42
vs. 9). On an average, the patients had 3.2 previous TUR
procedures (1–8). Previous “worst” histology revealed CIS
in 33 patients, grade 3 in 24 patients, and T1 in 20 patients
(some patients had more than one of these histopathologic
characteristics). Previous intravesical treatments included
BCG (n = 34), MMC (n = 11), epirubicin (n =4 ) ,  g e m c i t a -
bine (n = 3), Keyhole–Limpet hemocyanin (KLH) (n =1 ) ,
valrubicin (n = 1) and radiation therapy (n =1 ) .  O f  t h e  3 4World J Urol (2009) 27:319–324 321
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patients previously treated with BCG, 17 were BCG refrac-
tory, 2 BCG intolerant and 15 patients relapsed (3 patients
within 12 months, 6 patients between 12 and 24 months,
and 6 patients after 24 months). Twenty-four patients had
concomitant papillary tumors: TaG1 (n =1 ) ,  T a G 2  ( n =6 ) ,
TaG3 (n =8 ) ,  T 1 G 2  ( n =4 )  a n d  T 1 G 3  ( n =5 ) .
Eighteen patients received the prophylactic schedule
(twice 20 mg MMC), and 33 patients received the ablative
schedule (twice 40 mg MMC) together with intravesical
hyperthermia. Apart form the MMC dose, all patients in all
centers were treated according to the same treatment proto-
col. The mean total number of hyperthermia treatments was
10.0 (2–21). Two patients dropped out during initial treat-
ment (1 patient with hematuria after the second treatment,
and one patient with a false route after the fourth treatment)
and did not receive the initial six instillations. These two
patients were not considered for eYcacy.
EYcacy
In total, 49 patients remained available for treatment
response analysis. Of these patients, 45 (92%) had a com-
plete biopsy and cytology proven disappearance of CIS at
3 months. In two additional patients CIS disappeared but
the concomitant papillary tumor persisted. There was no
diVerence in response between patients with and without
concomitant papillary tumors (P = 0.94, data not shown),
irrespective whether the papillary tumor was pTa or pT1.
There was also no diVerence in response between patients
who were of were not BCG failures, irrespective of the type
of BCG failure (BCG resistant or early or late BCG fail-
ures, P = 0.63, data not shown). Since the 2-year results of
the 20 mg (prophylactic, n = 19) and 40 mg (ablative,
n = 26) regimens are also not signiWcantly diVerent
(P = 0.10, data not shown) these groups are analyzed
together. Of all 45 complete responders additional follow-
up is available with a mean follow-up of 27 (3–77, median
22) months. Of these 45 patients, 22 (49%) had a recur-
rence. Five of the patients had a cystectomy because of
recurrent T1 (n = 1) or >T1 (n = 4) tumor, after, respec-
tively, 11 and, 12 and 13 and, 18 months. One patient had a
cystectomy due to a contracted bladder, but he was tumor
free. The other 17 patients recurred with pure CIS (n =5 ) ,
T1 + CIS (n =1 ) ,  T a+C I S  ( n =2 ) ,  p T 1  ( n =3 ) ,  p T a  ( n =5 )
and pTx (n = 1). These patients were treated conserva-
tively.
Safety
Safety of chemotherapy treatment combined with micro-
wave hyperthermia was previously published [18]. Side
eVects in this study also were generally mild and transient,
and included mainly pain and bladder spasms during
treatment and irritative bladder symptoms for 1–2 days
thereafter. Side eVects had virtually no inXuence on the
treatment plan: as mentioned above, one patient stopped
treatment due to hematuria, one treatment session was
delayed for 1 week and one session was shortened. Adverse
events could not be graded according to the common toxic-
ity criteria retrospectively. Frequency of events is given in
Table 1.
Discussion
As indicated in the introduction international guidelines
advise to treat CIS patients with maintenance intravesical
BCG, since it appears to be able to prevent or delay disease
progression. However, the possibilities in case of BCG-
refractory CIS are limited.
Intravesical chemotherapy has been studied. Valrubicin
is the only FDA approved drug for patients with CIS-failing
intravesical therapy such as BCG. This was based on a
phase-II study with 90 patients [9]. After a year of follow-
up 21% had a complete response, which decreased to 8%
after 2 years. A marker lesion study in refractory patients
conWrmed initial potential of valrubicin, since 18/39 (46%)
patients were free of disease after 3 months [20]. However,
due to several reasons, valrubicin is not used currently.
Intravesical gemcitabine was also used in BCG-refractory
patients resulting in three small series. In one study with 18
patients (of whom 12 had pure CIS, 2 T1 + CIS), 11
patients showed negative biopsies after treatment, of whom
7 also had negative cytology [10]. In another recent phase-
II study 7 of 16 high-risk patients (not speciWed) remained
recurrence-free at 12 months [21]. Fifteen of 30 patients
(23 CIS, 4 Ta high grade, 3 T1) with NMIBC that were
BCG refractory (27) or BCG intolerant (3) had a complete
response in a study by Dalbagni et al. [22]. The 1-year
recurrence-free survival rate for patients with a complete
response was 21%.
Table 1 Session-related adverse events, measured per session
The total number of treatments given to the study group is 503
Adverse event Number Rate 
(% per session)
Pain 64 12.7
Bladder spasms 66 13.1
Dysuria 31 6.2
Hematuria 15 3.0
DiYcult catheter insertion 1 0.2
Urge/incontinence during treatment 2 0.4
Frequency/urgency 8 1.6
Nocturia 11 2.2322 World J Urol (2009) 27:319–324
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Immunotherapy in BCG failures is also reported. Bropir-
imine, an oral immunomodulator, was studied in BCG-
resistant CIS in a phase-II trial [23]. Fourteen out of 47
BCG-resistant patients showed a complete response with a
median duration of more than 12 months. Unfortunately, no
further evaluation of the drug has been done. The combina-
tion of interferon (IFN)-alpha and BCG for BCG failures
has been the subject of a large multi-center phase-II trial
[24]. In all, 467 patients failing BCG were treated with low-
dose BCG plus IFN. Twenty-seven percent of these patients
had isolated or concomitant CIS. With a median follow-up
of 24 months, 45% remained tumor-free, compared with
59% of the 536 patients in the BCG naïve group. Although
there was no sub-analysis for CIS patients, CIS did not sig-
niWcantly aVect outcome in a multivariate analysis. Patients
treated with two or more courses of BCG did not respond
well to BCG plus IFN, suggesting that this group of
patients should go on to cystectomy.
A recent method of device-assisted intravesical therapy is
PDT, which combines photo sensitizers that selectively bind
to tumors and a powerful intravesical light source to destroy
tumors. Waidelich et al. [25] used PDT with oral 5-amino-
levulinic acid (5-ALA) in Wve BCG-failing CIS patients, and
found three patients recurrence-free after a median follow-up
of 36 months. Intravesical 5-ALA was studied in 10 BCG
failures (presence of CIS not speciWed) of which four
remained tumor-free after an average follow-up of
11.8 months [13]. EMDA is based on the concept of tempo-
rarily breaching the urothelial barrier of the bladder and
enhancing penetration of drugs, among which MMC, in a
controllable manner [26]. Di Stasi et al. [14] performed a
randomized controlled trial in 212 patients with stage T1
NMIBC, comparing BCG alone (105 patients, 28 with con-
comitant CIS) with sequential BCG and MMC/EMDA (107
patients, 29 with concomitant CIS), with maintenance ther-
apy in both arms. This study found a signiWcantly higher dis-
ease-free interval, lower recurrence rate, lower progression
rate and lower disease-speciWc mortality in favor of sequen-
tial BCG and MMC/EMDA. Although not designed to assess
complete response rates of patients with CIS, 12/28 (42.9%)
patients treated with BCG alone and 16/28 (55.2%) patients
treated with sequential BCG and EMDA/MMC obtained a
complete response at 3 months, and respectively 16/28
(57.1%) patients and 20/29 (69.0%) patients at 6 months.
Limited and disappointing information is available on
the use of intravesical MMC in BCG failures. The Swedish-
Norwegian bladder cancer group compared MMC and
BCG in NMIBC patients and treatment failures were
allowed to cross over [27]. Twenty-one BCG failures
changed to MMC therapy, but only four remained recur-
rence-free with a median follow-up of 64 months.
In all, conservative therapy in patients with BCG-refrac-
tory CIS remains largely experimental, and indeed guide-
lines advise cystectomy as a treatment of choice for CIS
failing adequate BCG. On the other hand, cystectomy
remains major surgery with mortality and morbidity. Pros-
tate sparing cystectomy improves outcome of erectile func-
tion, but oncological outcome might be hampered [28].
Another approach is an attempt to improve the eYcacy of
intravesical MMC with devices such as EMDA or intraves-
ical bladder wall hyperthermia (Synergo®). In patients with
papillary tumors failing BCG thermochemotherapy showed
promising results [18]. In a group of 41 BCG-failing
patients the 1 and 2 years recurrence rates after a year of
thermochemotherapy were 23 and 41%, respectively. In
this study, 34 of the 51 patients with CIS were BCG pre-
treated, with an initial CR rate after 3 months of 92%,
which was still more than 50% after 2 years of follow-up.
Conclusions
The current report speciWcally looked at the results of the
combination of intravesical hyperthermia and chemotherapy
in patients with (mainly BCG failing) CIS of the urinary
bladder. Side eVects were mild and transient as expected and
reported earlier [18]. The initial response rate was 92% (45/
49), and in two additional patients CIS disappeared, whereas
papillary tumors did not. Although numbers are small, the
risk of tumor progression is low during this conservative
treatment, suggesting that this approach could be suggested
to a patient before considering cystectomy. Limitations are
obviously the retrospective nature of the study and the sam-
ple size. It took several years and a number of centers to col-
lect these (BCG failing) CIS patients. Not only CIS patients
are not very common, also the hyperthermia equipment is
still not commonly available. This is predominantly a cost
issue, not a logistical issue or patients acceptance. Another
limitation is the lack of review pathology. CIS, on the other
hand, is a disease with a high inter-observer agreement [29],
so the inXuence of review pathology for this group of
patients seems small. In all, although CIS is an infrequent
disease, considering the limited existing of conservative
alternatives in these patients and the impact of radical sur-
gery, thermochemotherapy deWnitely deserves further study
as conservative alternative in these patients.
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